Cargando…
A Review of Immune-Mediated Adverse Events in Melanoma
The use of checkpoint inhibitor-based immunotherapy has transformed the treatment landscape for melanoma as well as many other cancer types. With the ability to potentiate tumor-specific immune responses, these agents can result in durable tumor control. However, this activation of the immune system...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359990/ https://www.ncbi.nlm.nih.gov/pubmed/32699983 http://dx.doi.org/10.1007/s40487-019-0096-8 |
_version_ | 1783559147871010816 |
---|---|
author | Kennedy, Lucy Boyce Salama, April K. S. |
author_facet | Kennedy, Lucy Boyce Salama, April K. S. |
author_sort | Kennedy, Lucy Boyce |
collection | PubMed |
description | The use of checkpoint inhibitor-based immunotherapy has transformed the treatment landscape for melanoma as well as many other cancer types. With the ability to potentiate tumor-specific immune responses, these agents can result in durable tumor control. However, this activation of the immune system can lead to a unique constellation of side effects, distinct from other cancer therapies, collectively termed immune-mediated adverse events (irAEs). This review will focus on irAEs and guidelines for management related to the most clinically relevant checkpoint inhibitors, those that target programmed death receptor-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4). |
format | Online Article Text |
id | pubmed-7359990 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-73599902020-07-20 A Review of Immune-Mediated Adverse Events in Melanoma Kennedy, Lucy Boyce Salama, April K. S. Oncol Ther Review The use of checkpoint inhibitor-based immunotherapy has transformed the treatment landscape for melanoma as well as many other cancer types. With the ability to potentiate tumor-specific immune responses, these agents can result in durable tumor control. However, this activation of the immune system can lead to a unique constellation of side effects, distinct from other cancer therapies, collectively termed immune-mediated adverse events (irAEs). This review will focus on irAEs and guidelines for management related to the most clinically relevant checkpoint inhibitors, those that target programmed death receptor-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4). Springer Healthcare 2019-07-08 /pmc/articles/PMC7359990/ /pubmed/32699983 http://dx.doi.org/10.1007/s40487-019-0096-8 Text en © The Author(s) 2019 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Kennedy, Lucy Boyce Salama, April K. S. A Review of Immune-Mediated Adverse Events in Melanoma |
title | A Review of Immune-Mediated Adverse Events in Melanoma |
title_full | A Review of Immune-Mediated Adverse Events in Melanoma |
title_fullStr | A Review of Immune-Mediated Adverse Events in Melanoma |
title_full_unstemmed | A Review of Immune-Mediated Adverse Events in Melanoma |
title_short | A Review of Immune-Mediated Adverse Events in Melanoma |
title_sort | review of immune-mediated adverse events in melanoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359990/ https://www.ncbi.nlm.nih.gov/pubmed/32699983 http://dx.doi.org/10.1007/s40487-019-0096-8 |
work_keys_str_mv | AT kennedylucyboyce areviewofimmunemediatedadverseeventsinmelanoma AT salamaaprilks areviewofimmunemediatedadverseeventsinmelanoma AT kennedylucyboyce reviewofimmunemediatedadverseeventsinmelanoma AT salamaaprilks reviewofimmunemediatedadverseeventsinmelanoma |